Moreover, patients with diabetes might have more medical encounters and therefore are more strictly monitored, and glucose-lowering drugs recently adopted as first line therapy in high-CV risk T2D patients, such as SGLT2i and glucagon-like peptide-1 receptor agonists (GLP-1 RA), have demonstrated a favorable impact on renal outcomes [31–33]. This evidence concerns the gene GLP1R and diabetes mellitus.